Ariskon Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 1.26 M
- Company Age 17 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.90 M
- Revenue Growth -36.09%
- Profit Growth 4.95%
- Ebitda 73.77%
- Net Worth 3.67%
- Total Assets 0.37%
About Ariskon Pharma
Ariskon Pharma Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 April 2007 and has a history of 17 years and ten months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.26 M.
The company currently has active open charges totaling ₹4.90 M.
Dinesh Singh and Barun Singh serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232DL2007PTC161598
-
Company No.
161598
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 Apr 2007
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Ariskon Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dinesh Singh
|
Director | 03-Apr-2007 | Current |
|
Barun Singh
|
Director | 03-Apr-2007 | Current |
Financial Performance of Ariskon Pharma.
Ariskon Pharma Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 36.09% decrease. The company also saw a slight improvement in profitability, with a 4.95% increase in profit. The company's net worth moved up by a moderate rise of 3.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ariskon Pharma?
In 2018, Ariskon Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Jc Lifecare Private LimitedDinesh Singh is a mutual person
-
Noksira Pharma Private LimitedDinesh Singh and Barun Singh are mutual person
Charges (Loans)
₹4.90 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.46 Cr
- Union Bank Of India : 0.03 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Jan 2023 | Others | ₹0.60 M | Open |
| 30 May 2020 | Others | ₹4.00 M | Open |
| 05 Dec 2011 | Union Bank Of India | ₹0.30 M | Open |
How Many Employees Work at Ariskon Pharma?
Ariskon Pharma has a workforce of 8 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ariskon Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ariskon Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
